Fig. 6: MALAT1 enhances ferroptosis sensitivity in HBX-expressing tumors and is negatively correlated with SLC7A11 in HBV-infected DLBCL patients.
From: LncRNA MALAT1 promotes Erastin-induced ferroptosis in the HBV-infected diffuse large B-cell lymphoma

A Morphological diagrams of tumors in different groups were excised at day 24. B The tumor volume of Ctrl, HBX, and HBX+MALAT1 groups was calculated every 3 days with or without IKE/liproxstain treatment. “*” represented the significance of HBX+IKE versus Ctrl+IKE. “#” represented the significance of HBX+MALAT1+IKE versus HBX+IKE. C The excised tumor weight of Ctrl, HBX, and HBX+MALAT1 groups at day 24 after IKE/liproxstain treatment. “*” represented the significance of HBX+IKE versus Ctrl+IKE. “#” represented the significance of HBX+MALAT1+IKE versus HBX+IKE. D Immunohistochemical detection of 4-HNE in excised tumors. Black scale bar: 100 μm. E qRT-PCR analysis for the expression of MALAT1 expression in the GCB-type DLBCL patients with (n = 3) or without (n = 5) HBV infection. F Immunohistochemical detection of SLC7A11 expression in the GCB-type DLBCL patients with (n = 3) or without (n = 5) HBV infection. Black scale bar: 100 μm. G Pearson correlation analysis between MALAT1 and SLC7A11 expression. The results were determined in triplicate, and the error bars represented the mean ± SD. */# P < 0.05, **/## P < 0.01, and ***/### P < 0.001.